|
|
IL-6/STAT3信号通路在非小细胞肺癌发生和治疗中的进展
|
Abstract:
IL-6/STAT3通路是非小细胞肺癌发展的关键途径之一，可通过参与癌细胞的抗凋亡、增殖及肿瘤血管生成等多种恶性表型促进肿瘤发展。此外，临床研究表明，IL-6/STAT3信号通路与非小细胞肺癌的化疗、靶向及放疗耐药相关，针对IL-6/STAT3信号通路的靶向药物对非小细胞肺癌的治疗有益，有望成为治疗非小细胞肺癌的有效药物。深入了解IL-6/STAT3信号通路与非小细胞肺癌的关系有助于阐明非小细胞肺癌发病机制，并为其治疗提供新方向。本文就该通路在非小细胞肺癌发展及治疗中的最新进展作一综述。
The IL‐6/STAT3 pathway is one of the key pathways in the development of non-small cell lung can-cer (NSCLC), which can promote the development of tumor by participating in various malignant phenotypes such as anti-apoptosis, proliferation and tumor angiogenesis. In addition, clinical stud-ies have shown that IL‐6/STAT3 signaling pathway is associated with chemotherapy, targeting and radiotherapy resistance of NSCLC. Targeted drugs targeting IL‐6/STAT3 signaling pathway are ben-eficial for the treatment of NSCLC and are expected to be effective drugs for the treatment of NSCLC. A deeper understanding of the relationship between IL-6/STAT3 signaling pathway and NSCLC will help clarify the pathogenesis of NSCLC and provide a new direction for its treatment. This article re-views the latest progress of this pathway in the development and treatment of non-small cell lung cancer.
| [1] | 李涛, 母前途, 唐蕾. 血清肿瘤标志物CEA、ProGRP、SCC水平联合测定MSCT检查对肺癌的诊断效能分析[J]. 中国CT和MRI杂志, 2021, 19(11): 68-69+78. |
| [2] | Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [Published Correction Appears in CA Cancer J Clin. 2020 Jul; 70(4): 313]. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492 |
| [3] | 陈琼, 刘曙正, 郭兰伟, 曹小琴, 郑黎阳, 徐慧芳, 孙喜斌, 张韶凯, 张建功. 2016年河南省恶性肿瘤的发病与死亡分析[J]. 中国肿瘤, 2020, 29(8): 571-578. |
| [4] | 苏雷, 魏秀芹. 从我国肺癌防控发展看早期肺癌的诊疗策略[J]. 医学研究杂志, 2020, 49(9): 1-5. |
| [5] | Akhtar-Danesh, N., Akh-tar-Danseh, G.G., Seow, H.Y., Shakeel, S. and Finley, C. (2019) Trends in Survival Based on Treatment Modality in Non-Small Cell Lung Cancer Patients: A Population-Based Study. Cancer Investigation, 37, 355-366. https://doi.org/10.1080/07357907.2019.1653465 |
| [6] | Zheng, Q., Dong, H., Mo, J., et al. (2021) A Novel STAT3 Inhibitor W2014-S Regresses Human Non-Small Cell Lung Cancer Xenografts and Sensitizes EGFR-TKI Acquired Re-sistance. Theranostics, 11, 824-840.
https://doi.org/10.7150/thno.49600 |
| [7] | Harada, D., Takigawa, N. and Kiura, K. (2014) The Role of STAT3 in Non-Small Cell Lung Cancer. Cancers (Basel), 6, 708-722. https://doi.org/10.3390/cancers6020708 |
| [8] | Zhou, J., Qu, Z., Yan, S., et al. (2015) Differential Roles of STAT3 in the Initiation and Growth of Lung Cancer. Oncogene, 34, 3804-3814. https://doi.org/10.1038/onc.2014.318 |
| [9] | Kishimoto, T. (2010) IL-6: From Its Discovery to Clinical Applications. International Immunology, 22, 347-352.
https://doi.org/10.1093/intimm/dxq030 |
| [10] | 陈亮, 盛修贵. IL-6/STAT3信号通路与卵巢癌关系研究进展[J]. 中华肿瘤防治杂志, 2015, 22(15): 1253-1256.
DOI: 10. 16073/j. cnki. cjcpt. 2015. 15. 020. |
| [11] | Johnson, D.E., O’Keefe, R.A. and Grandis, J.R. (2018) Targeting the IL-6/JAK/STAT3 Signalling Axis in Cancer. Nature Reviews Clinical Oncology, 15, 234-248. https://doi.org/10.1038/nrclinonc.2018.8 |
| [12] | Hunter, C.A. and Jones, S.A. (2015) IL-6 as a Keystone Cytokine in Health and Disease [Published Correction Appears in Nat Immunol. 2017 Oct 18, 18(11): 1271]. Nature Immunology, 16, 448-457. https://doi.org/10.1038/ni.3153 |
| [13] | Prenissl, N., Lokau, J., Rose-John, S., Haybaeck, J. and Garbers, C. (2019) Therapeutic Blockade of the Interleukin-6 Receptor (IL-6R) Allows sIL-6R Generation by Proteolytic Cleavage. Cytokine, 114, 1-5.
https://doi.org/10.1016/j.cyto.2018.11.023 |
| [14] | Zunke, F. and Rose-John, S. (2017) The Shedding Protease ADAM17: Physiology and Pathophysiology. Biochimica et Biophysica Acta—Molecular Cell Research, 1864, 2059-2070. https://doi.org/10.1016/j.bbamcr.2017.07.001 |
| [15] | Mauer, J., Denson, J.L. and Brüning, J.C. (2015) Versatile Functions for IL-6 in Metabolism and Cancer. Trends in Immunology, 36, 92-101. https://doi.org/10.1016/j.it.2014.12.008 |
| [16] | Narazaki, M. and Kishimoto, T. (2018) The Two-Faced Cytokine IL-6 in Host Defense and Diseases. International Journal of Molecular Sciences, 19, Article No. 3528. https://doi.org/10.3390/ijms19113528 |
| [17] | Aparicio-Siegmund, S., Deseke, M., Lickert, A. and Garbers, C. (2017) Trans-Signaling of Interleukin-6 (IL-6) Is Mediated by the Soluble IL-6 Receptor, But Not by Soluble CD5. Biochemical and Biophysical Research Communications, 484, 808-812. https://doi.org/10.1016/j.bbrc.2017.01.174 |
| [18] | Baran, P., Hansen, S., Waetzig, G.H., Akbarzadeh, M., et al. (2018) The Balance of Interleukin (IL)-6, IL-6 Soluble IL-6 Re-ceptor (sIL-6R), and IL-6 sIL-6R sgp130 Complexes Allows Simultaneous Classic and Trans-Signaling. Journal of Bio-logical Chemistry, 293, 6762-6775. https://doi.org/10.1074/jbc.RA117.001163 |
| [19] | Becker, C., Fantini, M.C., Wirtz, S., et al. (2005) IL-6 Signaling Promotes Tumor Growth in Colorectal Cancer. Cell Cycle, 4, 217-220. https://doi.org/10.4161/cc.4.2.1413 |
| [20] | Zarogoulidis, P., Yarmus, L., Darwiche, K., et al. (2013) Interleukin-6 Cytokine: A Multifunctional Glycoprotein for Cancer. Immunome Research, 9, Article No. 16535. https://doi.org/10.4172/1745-7580.1000062 |
| [21] | Takizawa, H., Ohtoshi, T., Ohta, K., et al. (1993) Growth Inhibi-tion of Human Lung Cancer Cell Lines by Interleukin 6 in Vitro: A Possible Role in Tumor Growth via an Autocrine Mechanism. Cancer Research, 53, 4175-4181. |
| [22] | 付坚, 方伟岗, 郑杰, 钟镐镐, 衡万杰, 吴秉铨. 自泌性白细胞介素-6对人肺腺癌细胞系PAa生长的影响[J]. 中华肿瘤杂志, 1997(1): 46-49. |
| [23] | Liu, W., Wang, H., Bai, F., et al. (2020) IL-6 Promotes Metastasis of Non-Small-Cell Lung Cancer by Up-Regulating TIM-4 via NF-κB. Cell Prolifer-ation, 53, e12776. https://doi.org/10.1111/cpr.12776 |
| [24] | An, J., Gu, Q., Cao, L., et al. (2021) Serum IL-6 as a Vital Predictor of Severe Lung Cancer. Annals of Palliative Medicine, 10, 202-209. https://doi.org/10.21037/apm-20-2229 |
| [25] | Ke, W., Zhang, L. and Dai, Y. (2020) The Role of IL-6 in Immuno-therapy of Non-Small Cell Lung Cancer (NSCLC) with Immune-Related Adverse Events (irAEs). Thoracic Cancer, 11, 835-839.
https://doi.org/10.1111/1759-7714.13341 |
| [26] | Qu, Z., Sun, F., Zhou, J., Li, L., Shapiro, S.D. and Xiao, G. (2015) Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer. Cancer Research, 75, 3209-3215. https://doi.org/10.1158/0008-5472.CAN-14-3042 |
| [27] | Jing, B., Wang, T., Sun, B., et al. (2020) IL6/STAT3 Sig-naling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung. Cancer Research, 80, 784-797. https://doi.org/10.1158/0008-5472.CAN-19-2013 |
| [28] | Li, Y., Du, H., Qin, Y., Roberts, J., Cummings, O.W. and Yan, C. (2007) Activation of the Signal Transducers and Activators of the Transcription 3 Pathway in Alveolar Epithelial Cells Induces Inflammation and Adenocarcinomas in Mouse Lung. Cancer Research, 67, 8494-8503. https://doi.org/10.1158/0008-5472.CAN-07-0647 |
| [29] | Song, L., Turkson, J., Karras, J.G., Jove, R. and Haura, E.B. (2003) Activation of Stat3 by Receptor Tyrosine Kinases and Cytokines Regulates Survival in Human Non-Small Cell Carcinoma Cells. Oncogene, 22, 4150-4165.
https://doi.org/10.1038/sj.onc.1206479 |
| [30] | Zimmer, S., Kahl, P., Buhl, T.M., et al. (2009) Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer Influence Downstream Akt, MAPK and Stat3 Signaling. Journal of Cancer Research and Clinical Oncology, 135, 723-730. https://doi.org/10.1007/s00432-008-0509-9 |
| [31] | Looyenga, B.D., Hutchings, D., Cherni, I., Kingsley, C., Weiss, G.J. and Mackeigan, J.P. (2012) STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma. PLOS ONE, 7, e30820.
https://doi.org/10.1371/journal.pone.0030820 |
| [32] | Greulich, H., Chen, T.H., Feng, W., et al. (2005) Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants. PLOS Medicine, 2, e313. https://doi.org/10.1371/journal.pmed.0020313 |
| [33] | Xu, Y.H. and Lu, S. (2014) A Meta-Analysis of STAT3 and Phospho-STAT3 Expression and Survival of Patients with Non-Small-Cell Lung Cancer. European Journal of Surgical Oncology, 40, 311-317.
https://doi.org/10.1016/j.ejso.2013.11.012 |
| [34] | Zhao, M., Gao, F.H., Wang, J.Y., et al. (2011) JAK2/STAT3 Sig-naling Pathway Activation Mediates Tumor Angiogenesis by Upregulation of VEGF and bFGF in Non-Small-Cell Lung Cancer. Lung Cancer, 73, 366-374.
https://doi.org/10.1016/j.lungcan.2011.01.002 |
| [35] | Bremnes, R.M., D？nnem, T., Al-Saad, S., et al. (2011) The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 6, 209-217. https://doi.org/10.1097/JTO.0b013e3181f8a1bd |
| [36] | Kalluri, R. (2016) The Biology and Function of Fibroblasts in Cancer. Nature Reviews Cancer, 16, 582-598.
https://doi.org/10.1038/nrc.2016.73 |
| [37] | Altorki, N.K., Markowitz, G.J., Gao, D., et al. (2019) The Lung Microen-vironment: An Important Regulator of Tumour Growth and Metastasis. Nature Reviews Cancer, 19, 9-31. https://doi.org/10.1038/s41568-018-0081-9 |
| [38] | Ambros, V. (2004) The Functions of Animal microRNAs. Nature, 431, 350-355. https://doi.org/10.1038/nature02871 |
| [39] | Calin, G.A. and Croce, C.M. (2006) MicroRNA Signa-tures in Human Cancers. Nature Reviews Cancer, 6, 857-866.
https://doi.org/10.1038/nrc1997 |
| [40] | Hayashita, Y., Osada, H., Tatematsu, Y., et al. (2005) A Polycistronic mi-croRNA Cluster, miR-17-92, Is Overexpressed in Human Lung Cancers and Enhances Cell Proliferation. Cancer Re-search, 65, 9628-9632.
https://doi.org/10.1158/0008-5472.CAN-05-2352 |
| [41] | Hatley, M.E., Patrick, D.M., Garcia, M.R., et al. (2010) Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21. Cancer Cell, 18, 282-293. https://doi.org/10.1016/j.ccr.2010.08.013 |
| [42] | Garofalo, M., Di Leva, G., Romano, G., et al. (2009) miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation. Cancer Cell, 16, 498-509.
https://doi.org/10.1016/j.ccr.2009.10.014 |
| [43] | Takamizawa, J., Konishi, H., Yanagisawa, K., et al. (2004) Reduced Expression of the let-7 microRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival. Cancer Research, 64, 3753-3756.
https://doi.org/10.1158/0008-5472.CAN-04-0637 |
| [44] | Yang, J., Lan, H., Huang, X., Liu, B. and Tong, Y. (2012) MicroRNA-126 Inhibits Tumor Cell Growth and Its Expression Level Correlates with Poor Survival in Non-Small Cell Lung Cancer Patients. PLOS ONE, 7, e42978.
https://doi.org/10.1371/journal.pone.0042978 |
| [45] | Ke, Y., Zhao, W., Xiong, J. and Cao, R. (2013) Downregulation of miR-16 Promotes Growth and Motility by Targeting HDGF in Non-Small Cell Lung Cancer Cells. FEBS Letters, 587, 3153-3157.
https://doi.org/10.1016/j.febslet.2013.08.010 |
| [46] | Fernandez, S., Risolino, M., Mandia, N., et al. (2015) miR-340 Inhibits Tumor Cell Proliferation and Induces Apoptosis by Targeting Multiple Negative Regulators of p27 in Non-Small Cell Lung Cancer. Oncogene, 34, 3240-3250.
https://doi.org/10.1038/onc.2014.267 |
| [47] | Chen, Z., Zeng, H., Guo, Y., et al. (2010) miRNA-145 Inhibits Non-Small Cell Lung Cancer Cell Proliferation by Targeting c-Myc. Journal of Experimental & Clinical Cancer Re-search, 29, Article No. 151.
https://doi.org/10.1186/1756-9966-29-151 |
| [48] | Seol, H.S., Akiyama, Y., Shimada, S., et al. (2014) Epigenetic Si-lencing of microRNA-373 to Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer through IRAK2 and LAMP1 Axes. Cancer Letters, 353, 232-241.
https://doi.org/10.1016/j.canlet.2014.07.019 |
| [49] | Yang, Y., Ding, L., Hu, Q., et al. (2017) MicroRNA-218 Func-tions as a Tumor Suppressor in Lung Cancer by Targeting IL-6/STAT3 and Negatively Correlates with Poor Prognosis. Molecular Cancer, 16, Article No. 141.
https://doi.org/10.1186/s12943-017-0710-z |
| [50] | O’Shea, J.J., Holland, S.M. and Staudt, L.M. (2013) JAKs and STATs in Immunity, Immunodeficiency, and Cancer. The New England Journal of Medicine, 368, 161-170. https://doi.org/10.1056/NEJMra1202117 |
| [51] | Yu, H. and Jove, R. (2004) The STATs of Cancer—New Molecular Targets Come of Age. Nature Reviews Cancer, 4, 97-105. https://doi.org/10.1038/nrc1275 |
| [52] | Bowman, T., Gar-cia, R., Turkson, J. and Jove, R. (2000) STATs in Oncogenesis. Oncogene, 19, 2474-2488.
https://doi.org/10.1038/sj.onc.1203527 |
| [53] | Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., et al. (1999) Stat3 as an Oncogene [Published Correction Appears in Cell 1999 Oct 15, 99(2): 239]. Cell, 98, 295-303. https://doi.org/10.1016/S0092-8674(00)81959-5 |
| [54] | Haura, E.B., Zheng, Z., Song, L., Cantor, A. and Bepler, G. (2005) Activated Epidermal Growth Factor Receptor-Stat-3 Signaling Promotes Tumor Survival in Vivo in Non-Small Cell Lung Cancer. Clinical Cancer Research, 11, 8288-8294. https://doi.org/10.1158/1078-0432.CCR-05-0827 |
| [55] | Cai, L., Zhang, G., Tong, X., et al. (2010) Growth Inhibi-tion of Human Ovarian Cancer Cells by Blocking STAT3 Activation with Small Interfering RNA. The European Journal of Obstetrics & Gynecology and Reproductive Biology, 148, 73-80. https://doi.org/10.1016/j.ejogrb.2009.09.018 |
| [56] | Burke, W.M., Jin, X., Lin, H.J., et al. (2001) Inhibition of Con-stitutively Active Stat3 Suppresses Growth of Human Ovarian and Breast Cancer Cells. Oncogene, 20, 7925-7934. https://doi.org/10.1038/sj.onc.1204990 |
| [57] | Horiguchi, A., Asano, T., Kuroda, K., et al. (2010) STAT3 Inhibitor WP1066 as a Novel Therapeutic Agent for Renal Cell Carcinoma. British Journal of Cancer, 102, 1592-1599. https://doi.org/10.1038/sj.bjc.6605691 |
| [58] | Byers, L.A., Sen, B., Saigal, B., et al. (2009) Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer. Clinical Cancer Research, 15, 6852-6861. https://doi.org/10.1158/1078-0432.CCR-09-0767 |
| [59] | Chiu, H.C., Chou, D.L., Huang, C.T., et al. (2011) Sup-pression of Stat3 Activity Sensitizes Gefitinib-Resistant Non Small Cell Lung Cancer Cells. Biochemical Pharmacology, 81, 1263-1270. https://doi.org/10.1016/j.bcp.2011.03.003 |
| [60] | Song, L., Rawal, B., Nemeth, J.A. and Haura, E.B. (2011) JAK1 Activates STAT3 Activity in Non-Small-Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling. Molecular Cancer Therapeutics, 10, 481-494. https://doi.org/10.1158/1535-7163.MCT-10-0502 |
| [61] | Sen, B., Saigal, B., Parikh, N., Gallick, G. and Johnson, F.M. (2009) Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase-STAT3 Binding. Cancer Research, 69, 1958-1965. https://doi.org/10.1158/0008-5472.CAN-08-2944 |
| [62] | Barre, B., Vigneron, A., Perkins, N., Roninson, I.B., Gamelin, E. and Coqueret, O. (2007) The STAT3 Oncogene as a Predictive Marker of Drug Resistance. Trends in Mo-lecular Medicine, 13, 4-11.
https://doi.org/10.1016/j.molmed.2006.11.001 |
| [63] | Ikuta, K., Takemura, K., Kihara, M., et al. (2005) Overexpres-sion of Constitutive Signal Transducer and Activator of Transcription 3 mRNA in Cisplatin-Resistant Human Non-Small Cell Lung Cancer Cells. Oncology Reports, 13, 217-222. https://doi.org/10.3892/or.13.6.1229 |
| [64] | Su, W.P., Cheng, F.Y., Shieh, D.B., Yeh, C.S. and Su, W.C. (2012) PLGA Nanoparticles Codeliver Paclitaxel and Stat3 siRNA to Overcome Cellular Resistance in Lung Cancer Cells. International Journal of Nanomedicine, 7, 4269-4283.
https://doi.org/10.2147/IJN.S33666 |
| [65] | Kulesza, D.W., Carré, T., Chouaib, S. and Kaminska, B. (2013) Silencing of the Transcription Factor STAT3 Sensitizes Lung Cancer Cells to DNA Damaging Drugs, but Not to TNFα- and NK Cytotoxicity. Experimental Cell Research, 319, 506-516. https://doi.org/10.1016/j.yexcr.2012.11.005 |
| [66] | Zhang, W., Wan, M., Ma, L., Liu, X. and He, J. (2013) Protective Effects of ADAM8 against Cisplatin-Mediated Apoptosis in Non-Small-Cell Lung Cancer. Cell Biology International, 37, 47-53. https://doi.org/10.1002/cbin.10011 |
| [67] | Shen, Y., Devgan, G., Darnell, J.E. and Bromberg, J.F. (2001) Constitutively Activated Stat3 Protects Fibroblasts from Serum Withdrawal and UV-Induced Apoptosis and Antagonizes the Proapoptotic Effects of Activated Stat1. Proceedings of the National Academy of Sciences of the United States of America, 98, 1543-1548.
https://doi.org/10.1073/pnas.98.4.1543 |
| [68] | Sano, S., Chan, K.S., Kira, M., et al. (2005) Signal Transducer and Activator of Transcription 3 Is a Key Regulator of Keratinocyte Survival and Proliferation Following UV Irradiation. Cancer Research, 65, 5720-5729.
https://doi.org/10.1158/0008-5472.CAN-04-4359 |
| [69] | You, S., Li, R., Park, D., et al. (2014) Disruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer. Molecular Cancer Therapeutics, 13, 606-616. https://doi.org/10.1158/1535-7163.MCT-13-0608 |
| [70] | Sun, Y., Moretti, L., Giacalone, N.J., et al. (2011) Inhibi-tion of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models. Journal of Thoracic Oncology, 6, 699-706. https://doi.org/10.1097/JTO.0b013e31820d9d11 |
| [71] | Jin, H.O., Lee, Y.H., Park, J.A., et al. (2014) Blockage of Stat3 Enhances the Sensitivity of NSCLC Cells to PI3K/mTOR Inhibition. Biochemical and Biophysical Re-search Communications, 444, 502-508.
https://doi.org/10.1016/j.bbrc.2014.01.086 |
| [72] | Liu, Y., Huang, J., Li, W., Chen, Y., Liu, X. and Wang, J. (2018) Meta-Analysis of STAT3 and Phospho-STAT3 Expression and Survival of Patients with Breast Cancer. Oncotarget, 9, 13060-13067.
https://doi.org/10.18632/oncotarget.23962 |
| [73] | Haura, E.B., Sommers, E., Song, L., Chiappori, A. and Becker, A. (2010) A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance. Journal of Thoracic Oncology, 5, 1806-1814. https://doi.org/10.1097/JTO.0b013e3181f38f70 |
| [74] | Herbst, R.S., Morgensztern, D. and Boshoff, C. (2018) The Biology and Management of Non-Small Cell Lung Cancer. Nature, 553, 446-454. https://doi.org/10.1038/nature25183 |
| [75] | Hirsch, F.R., Scagliotti, G.V., Mulshine, J.L., et al. (2017) Lung Cancer: Current Therapies and New Targeted Treatments. The Lancet, 389, 299-311. https://doi.org/10.1016/S0140-6736(16)30958-8 |
| [76] | Slinger, E., Maussang, D., Schreiber, A., et al. (2010) HCMV-Encoded Chemokine Receptor US28 Mediates Proliferative Signaling through the IL-6-STAT3 Axis. Science Signaling, 3, ra58. https://doi.org/10.1126/scisignal.2001180 |
| [77] | Kim, S.M., Kwon, O.J., Hong, Y.K., et al. (2012) Activation of IL-6R/JAK1/STAT3 Signaling Induces de Novo Resistance to Irreversible EGFR Inhibitors in Non-Small Cell Lung Cancer with T790M Resistance Mutation. Molecular Cancer Therapeutics, 11, 2254-2264. https://doi.org/10.1158/1535-7163.MCT-12-0311 |
| [78] | Blackwell, T.S. and Christman, J.W. (1997) The Role of Nuclear Factor-Kappa B in Cytokine Gene Regulation. The American Journal of Respiratory Cell and Molecular Biology, 17, 3-9. https://doi.org/10.1165/ajrcmb.17.1.f132 |
